The government-backed Cell and Gene Therapy (CGT) Catapult has boasted that the UK’s pipeline of advanced therapy medicinal products continues to go from strength to strength.
There are currently 85 clinical trials and 875 pre-clinical research projects in cell and gene therapies ongoing in the UK, representing a 37% and 20% increase year-on-year respectively.
"We are building the world’s most complete advanced therapies ecosystem"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze